The biotech industry may be cooling off, but there’s still plenty to be excited about when it comes to the underlying ...

Novo Nordisk’s hopes of heralding a new era of obesity treatment with its next-generation CagriSema drug may be in doubt ...

Morgan Stanley analyst Laura Hindley upgraded Zealand Pharma (ZLDPF) to Overweight from Equal Weight with a DKK 750 price target The ...

Novo Nordisk’s phase III REDEFINE 2 study evaluating its next-gen subcutaneous obesity candidate, CagriSema, met its primary endpoint. CagriSema is a fixed-dose combination of a long-acting ...

Several weight loss drug stocks are sliding today as pharmaceutical companies battle for dominance in the booming GLP-1 ...

Roche is doubling down on competing for a slice of the rapidly growing GLP-1 pie. The Swiss pharma giant announced a deal worth up to $5.3 billion on Wednesday with Danish drugmaker Zealand Pharma to ...

Roche Holding said it would pay Danish biotechnology research company Zealand Pharma up to $5.3 billion under an agreement to ...

Investing.com -- Zealand Pharma shares surged more than 41% on Wednesday after announcing a $5.3 billion licensing deal with Roche for its GLP-1 obesity therapy petrelintide. "Lorem ipsum dolor sit ...

Investing.com -- Novo Nordisk (CSE:NOVOb) (NYSE:NVO) shares slumped Wednesday after Roche (SIX:ROG) struck a $5.3 billion deal to acquire rights to an obesity treatment from Denmark’s Zealand Pharma ...

Investing.com -- Novo Nordisk (CSE:NOVOb) (NYSE:NVO) shares slumped Wednesday after Roche (SIX:ROG) struck a $5.3 billion deal to acquire rights to an obesity treatment from Denmark’s Zealand Pharma A ...

Roche and Zealand reason petrelintide could deliver weight loss comparable to glucagon-like peptide 1 (GLP-1) receptor agonists but without the side effects associated with GLP-1 drugs.